Technology Bundle ID: TAB-2321

Diagnostic Assays and Methods of Use for Detection of Filarial Infection

Request More Info
Licensing Contact:
Primary Inventors: 
Thomas Nutman (NIAID)
Doran Fink (NIAID), Joseph Kubofcik (NIAID), Peter Burbelo (NIDCR)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Early-stage
  • Pre-clinical
Institute or Center: 

The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult Wuchereria bancrofti (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts. This new technology improves available detection methods through use of an isolated immunoreactive antigen, Wb123, from infective stage larvae (L3) Wb; which results in specific detection early in the infective cycle with reduced cross reactivity. This technology may see wide application in testing and surveillance of lymphatic filariasis as part of the effort to eliminate the disease worldwide.

  • Diagnostics testing
  • Infectious disease monitoring
  • Improved detection of early stage lymphatic filariasis


PCT Application PCT/US2011/58561
Filed on 2011-10-31
US Application 61/410,239
Filed on 2010-11-04
US Pat 9,068,993

Issued 2015-06-30


Bennuru S, et al.
PMID 20889885
Bennuru S, et al.
PMID 21606368
Fink DL, et al.
PMID 20980560
Senbagavalli P, et al.
PMID 21734131
Steel C, et al.
PMID 21559422


Sep 29, 2011

Data Source: